1 asset in Small Intestine Neuroendocrine Tumor, Well Differentiated, Low Or Intermediate Grade

Therapeutic assets addressing Small Intestine Neuroendocrine Tumor, Well Differentiated, Low Or Intermediate Grade, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Surufatinib Small Intestine Neuroendocrine Tumor, Well Differentiated, Low Or Intermediate Grade	Hutchmed	P2	CCC (53)